Microsoft (NASDAQ:MSFT) remains a dominant force in the world of tech. When investors think of mega-cap tech stocks, MSFT stock is one that simply has to be in the discussion. In that regard, and considering the stock’s weighting in major indices, it’s likely that most passive investors already have significant exposure to this name. In
In the last few years, short-squeeze stocks investing gained prominence in the euphoria of 2021. Retail investors targeted stocks that have a high short interest. When the stock started trending higher, shorts were covered, resulting in a massive rally in quick time. There were multibagger stories in a matter of weeks. Of course, GameStop (NYSE:GME)
Until recently Johnson & Johnson (NYSE:JNJ) stock was the most conservative investment you could make in the drugs space. It still is, but that’s no longer a compliment. There’s a lot more risk in it since it spun off its consumer business as Kenvue (NYSE:KVUE) on August 23. Since then JNJ stock is down 5%,
Urban Air Mobility (UAM) is on the cusp of transforming urban transportation, with the industry’s value projected to surge from $220 million in 2022 to an estimated $1.5 trillion over the next two decades. This signals an impressive compound annual growth rate (CAGR) exceeding 55%. This explosive growth underscores the potential of UAM to redefine
Of the 500 stocks listed in the benchmark S&P 500 index, only 51 (10%) are considered dividend kings and have increased their dividend payout to stockholders for 50 consecutive years or longer. Dividend kings are often stocks of long-established blue-chip companies that have prioritized returning capital to their shareholders through consistent dividend payments. These companies
After AMC (NYSE:AMC) announced on Sept. 26 that it would distribute Taylor Swift’s movie globally and over $100 million of advance tickets were purchased for the film, AMC stock soared 25%. Given that impressive rally, I believe that huge, record-breaking profits for AMC on the film are already baked into the stock. Moreover, the shares
C3.ai (NYSE:AI) stock has seen a significant year-to-date return of 123%. Despite reaching $49 earlier this year, AI stock has corrected to around $26 per share at the time of writing, presenting a potential entry point. With a 39% short interest in the free float, a short-squeeze rally is anticipated by some speculators. That’s an
Embarking on a steady sail through the riveting investment realm, the name Warren Buffett continues to spark enthusiasm. Steering the mighty ship of Berkshire Hathaway (NYSE:BRK-A, NYSE:BRK-B), Buffett maintains vigilant control over an awe-inspiring $340 billion investment portfolio. While harboring nearly $150 billion in cash, he stands ever-ready to pounce on burgeoning opportunities with a
Last Monday, a landmark U.S. trial against Alphabet’s Google (NASDAQ:GOOG, NASDAQ:GOOGL) began, and the case represents one of the first antitrust cases embarked upon by the U.S. Department of Justice against a large technology company in years. What does that have to do with MSFT stock? Now, core to the Justice Department’s case is how “distribution agreements”
Amazon (NASDAQ:AMZN) is one of the world’s largest and most diversified companies, with businesses ranging from e-commerce to cloud computing to healthcare. The company has been growing rapidly in recent years, generating over $538 billion in revenue and $13 billion in net income in the last twelve months. However, volatility and a souring macroeconomic outlook
Advanced Micro Devices’ (NASDAQ:AMD) CEO, Lisa Su, aims to challenge Nvidia’s (NASDAQ:NVDA) 85% market dominance in AI processors. AMD’s MI300 line focuses on inference solutions that analyze new data using pre-trained AI models. To achieve this, AMD must dispel the notion that Nvidia processors are better because of its software. But some, like Lamini, find
Pfizer (NYSE:PFE) stock steadily declined since the start of 2022. Many investors are staying away, but some may be wondering whether there’s merit in making PFE stock a bottom-fisher’s buy. Among healthcare stocks, this pharmaceutical giant is seemingly a bargain. Shares currently trade for just 10 times forward earnings. The stock also sports a very
Electric vehicle sales are set to accelerate. In fact, according to an Ernst & Young survey, nearly half of consumers in the United Sates (48%) plan to buy an electric vehicle in the next two years. That’s a 19% jump year throughout year just in the U.S. So, we wanted to look at some of
When you’re looking for good investment options in the fourth quarter, top tech stocks should be at the top of your list. And the best way to evaluate tech stocks is by using the Portfolio Grader. Tech companies, by nature, are innovative and, therefore, are in the best position to capitalize on emerging trends and
October is renowned for its potential to unsettle investors with significant market drops, a trend that continues from the previous month. Indeed, while certain stocks have shown an ability to weather volatility, some falling stocks are down and could still see greater declines. Here are three such stocks that have been down significantly recently and
One way to get portfolio exposure to both fossil fuels and clean energy is by owning Exxon Mobil (NYSE:XOM) stock. To a certain extent, XOM’s success depends on the ups and downs of the petroleum industry. Not everyone wants to ride out the oil market’s waves, so consider the risks and potential rewards before investing in
The seal of the U.S. Securities and Exchange Commission hangs on the wall at SEC headquarters in Washington, June 24, 2011. Jonathan Ernst | Reuters Securities traders are gathering in Washington. The big topic: trying to figure out what the Securities and Exchange Commission is doing. You know it’s bad when one of the session topics is
A box of Ozempic, a semaglutide injection drug used for treating Type 2 diabetes made by Novo Nordisk. George Frey | Reuters Check out the companies making big moves midday. Novo Nordisk — The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic’s kidney disease treatment trial after a committee said
Since going public in June 2021, SoFi Technologies (NASDAQ:SOFI) hasn’t met investor expectations. Despite a 59% drop from its IPO price, it rebounded in 2023, surging 98%. Before buying, it’s crucial to consider the pros and cons of this fintech stock. Moreover, SOFI has experienced a rollercoaster ride. Despite facing challenges due to the extended
The debt woes facing corporate America are real, as indicated by an increase in debt defaults. In July, Business Insider reported that 55 U.S. companies had defaulted within the first six months of the year, 53% higher than a year earlier. “A tougher credit environment combined with a full-blown recession could result in nearly a
- « Previous Page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- …
- 456
- Next Page »